- Home
- RERE vs LTGO Comparison
RERE vs LTGO Comparison
Compare RERE & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RERE | LTGO |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 832.8M | 924.9M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | RERE | LTGO |
|---|---|---|
| Price | $4.37 | $14.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.64 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 444.0K | 201.0K |
| Earning Date | 11-19-2026 | 11-19-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.40 | N/A |
| Revenue Next Year | $21.96 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $13.26 |
| 52 Week High | $6.47 | $25.93 |
Technical Indicators
Market Signals| Indicator | RERE | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 42.74 |
| Support Level | $3.79 | $13.50 |
| Resistance Level | $4.09 | $17.67 |
| Average True Range (ATR) | 0.14 | 1.39 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 88.46 | 29.71 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.